On 26th June, 2022, Board Chairman of Hua Boron Neutron Technology Co, Ltd., Party Chief of Nuclear Science and Technology Department of Xi’An JiaoTong University Wang Sheng, Deputy Chairman of the Board of Hua Boron Neutron Technology Co, Ltd. Yang Chengen, Executive Manager of marketing department Lu Wenpeng, Technical Director Yang Shanghui and Sales Director Liu Ziling visited Guangzhou RoyalLee Cancer Center with an emerging precision treatment technology- Boron Neutron Capture Therapy(BNCT).
Board Chairman of Guangzhou RoyalLee Cancer Center Li Min, President Wang Jichen, Vice President of Operation Zhou Zicheng, Purchasing Director Li Li and Director of Medical Administration Zhang Haiyuan extended a warm welcome to the visiting group and had a symposium to discuss new prospect in tumor treatment in China.
Fifth from the right side-Board Chairman of Hua Boron Neutron Technology Co, Ltd., Party Chief of Nuclear Science and Technology Department of Xi’An JiaoTong University Wang Sheng Fourth from the right side-Board Chairman of Guangzhou RoyalLee Cancer Center Li Min Fifth from the left side-President Wang Jichen
Wang Sheng got to know the Center as a whole and how far it had gone by a tour around the Center in the company of RoyalLee team. He highly rated pleasant environment, considerate service concept and customer-centered process. He reckoned that RoyalLee is a well-established facility eligible for undertaking top-line technologies.
In symposium, President Wang Jichen first expressed his heartfelt welcome to the visiting group.
“As a platform-based hospital, RoyalLee is committed to exploring new modality of medical service by introducing advanced treatment technologies and concept across the globe. RoyalLee, as a platform-based oncology giant, aspires to providing premium medical service for patients around the world with integration of prevention, diagnosis, treatment and rehabilitation”, he pointed out.
At present, RoyalLee made breakthroughs in iodine 125 particle implantation and Yttrium-90 technology in combating high-prevalence cancers in China. Notably, iodine 125 particle implantation was approved by associated regulator and was close to actual use in near future.
Wang Sheng expressed appreciation for hospitality of RoyalLee team. Then he walked through the status-quo and technological achievements of Hua Boron Neutron Technology and furthered this topic with Chairman Li Min and President Wang Jichen.
BNCT
Boron Neutron Capture Therapy, abbreviated as BNCT, is a emerging precision treatment technology rapidly growing in international tumor treatment field. It is capable of killing cancer cells at the cell level in virtue of biologically-targeted and heavy ion effect.
Compared with other cancer treatment methods, BNCT is competitive in three aspects. First, this therapy consumes less time and is efficient. Second, it proves to be safe. Last, it is widely applicable. Since 2001, clinical trialⅠandⅡof BNCT in treating head and neck cancer, glioma, melanoma and liver cancer have been completed all over the world. Now, one indication(inoperable local Stage IV or recurrent head and neck cancer) of the therapy has been approved for marketing.
In the future, the therapy is likely to more indications as new targeted probe and drug development steer towards more cancer types.
Chairman Li Min noted that he was glad to hear BNCT was well promoted inside the country. And he hoped to see people can have access to this premier and top-line technology. At the same time, he looked forward to more bilateral exchanges and prospects of bilateral cooperation in advanced tumor treatment technologies.